Can zaleplon be prescribed for nightly, long‑term use?

Zaleplon for Nightly, Long-Term Use

Zaleplon can be used nightly for chronic insomnia, but clinicians should be aware that FDA labeling indicates short-term use (7-10 days), while clinical practice guidelines and research evidence support longer-term nightly use with a relatively favorable safety profile compared to other hypnotics.

Guideline Recommendations

The American Academy of Sleep Medicine (AASM) 2017 guidelines provide a weak recommendation for zaleplon 10 mg as treatment for sleep onset insomnia in adults 1111. This recommendation is based on trials evaluating chronic insomnia, not just short-term use, indicating that the guideline panel considered evidence beyond the typical 7-10 day window.

Critical FDA Labeling Caveat

The FDA label explicitly states that failure of insomnia to remit after 7 to 10 days of treatment may indicate the presence of a primary psychiatric and/or medical illness that should be evaluated 22. This does not prohibit longer use—it mandates reassessment at that timepoint to ensure insomnia isn't masking another condition.

Evidence for Long-Term Use

Efficacy Data

• A 35-night sleep laboratory study demonstrated zaleplon 10 mg remained significantly more effective than placebo in reducing sleep latency at nights 29-30 1
• Open-label extension studies showed zaleplon maintained statistically significant improvements in sleep onset, duration, and number of awakenings for up to 12 months in elderly patients 3
• No tolerance to hypnotic effects developed during 5 weeks of treatment in controlled trials, or during 6-12 months in long-term studies 24

Safety Profile for Extended Use

The AASM guideline notes that zaleplon has a relatively benign side effect profile 1111:

• No significant withdrawal symptoms on Benzodiazepine Withdrawal Symptom Questionnaire 1111
• Minimal rebound insomnia: At 5-10 mg doses, no objective and minimal subjective evidence of rebound on first night after discontinuation 111
• No next-day impairment at recommended doses (5-10 mg) due to ultra-short half-life of ~1 hour 354
• Most common adverse events (headache, asthenia, fatigue) occurred at rates similar to placebo 111

Important Safety Warnings

Despite the favorable profile, the FDA label includes serious warnings that apply to both short and long-term use 22:

• Complex sleep behaviors (sleep-walking, sleep-driving) can occur at any point during treatment and may be fatal
• CNS depression is enhanced with alcohol or other CNS depressants
• Next-day impairment risk increases if taken with <7-8 hours of sleep remaining
• Elderly patients are at higher risk of falls due to drowsiness

Broader Context on Hypnotic Safety

The American College of Physicians 2016 guideline raises important concerns about all hypnotics used long-term 6:

• Many hypnotics have FDA indication only for short-term use, yet are prescribed long-term
• Hypnotics are associated with dementia, fractures, major injuries, and possibly cancer in observational studies
• Most patients continue to have symptoms exceeding enrollment thresholds even after treatment, indicating medications rarely achieve remission

However, zaleplon appears to have advantages over other hypnotics: The AASM evidence review found zaleplon had "weak objective evidence of efficacy...just below criteria for clinical significance" but concluded "benefits marginally outweigh harms" based on its safety profile 11.

Clinical Algorithm for Long-Term Zaleplon Use

1. Initial evaluation: Rule out primary psychiatric/medical causes of insomnia before starting
2. Start at lowest effective dose: 5 mg in elderly, 10 mg in non-elderly adults
3. Reassess at 7-10 days: If insomnia persists, evaluate for underlying conditions before continuing
4. Monitor for efficacy: Zaleplon primarily improves sleep onset, not maintenance—if patient needs sleep maintenance, consider alternatives
5. Ongoing monitoring:
   • Screen for complex sleep behaviors at each visit
   • Assess for tolerance (though unlikely based on evidence)
   • Evaluate continued need periodically
6. Patient counseling:
   • Take only with 7-8 hours available for sleep
   • Avoid alcohol and other CNS depressants
   • Do not drive or operate machinery if awakened before full sleep period

Bottom Line

Zaleplon can be prescribed for nightly, long-term use based on guideline recommendations and research evidence showing maintained efficacy and safety up to 12 months 13. The FDA's 7-10 day guidance is a checkpoint for reassessment, not an absolute limit. Zaleplon's ultra-short half-life, lack of withdrawal effects, minimal rebound insomnia, and absence of next-day impairment at recommended doses make it one of the safer options for chronic nightly use among hypnotics 11354. However, clinicians must counsel patients about serious risks (complex sleep behaviors, falls in elderly) and periodically reassess the need for continued pharmacotherapy 22.